Every material Form 8-K Intellia Therapeutics, Inc. has filed with the SEC since September 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Intellia Therapeutics reported third-quarter 2026 results, with collaboration revenue of $7.2 million, down from $13.8 million a year earlier, and a net loss of $127.5 million, up from $101.3 million. The company said cash, cash equivalents and marketable securities were $614.8 million at September 30, 2026, and that existing resources should fund operations at least into 2028.
Collaboration revenue fell to $7.2 million from $13.8 million, mainly due to lower Regeneron revenue.
Net loss was $127.5 million, including a $10.4 million unrealized loss from changes in investment fair value.
Cash and marketable securities were $614.8 million at September 30, 2026, which the company expects to fund operations at least into 2028.
FDA set a PDUFA target action date of March 10, 2027 for lonvo-z in HAE.
Intellia Therapeutics said the FDA accepted its Biologics License Application for lonvo-z, its investigational one-time treatment for hereditary angioedema, and granted Priority Review with a PDUFA target action date of March 10, 2027. The FDA also said it does not currently plan to hold an advisory committee meeting on the application. The milestone sets a defined regulatory timeline for a product the company says could be the first approved in vivo CRISPR-based therapy.
FDA accepted the BLA for lonvo-z and granted Priority Review
PDUFA target action date is March 10, 2027
FDA does not currently plan an advisory committee to discuss the application
Phase 3 HAELO trial met its primary and all key secondary endpoints, with an 87% reduction in mean monthly attacks versus placebo
On September 4, 2026, Intellia Therapeutics entered a five-year senior secured credit agreement with OrbiMed that provides up to $400 million, with $75 million drawn at closing. The remaining $325 million is available in tranches tied to FDA approval of lonvo-z, revenue targets and an equity fundraising target, plus an uncommitted $100 million that requires mutual agreement. The debt adds to Intellia's obligations, carries a floating-rate interest cost and is secured by substantially all of the company's assets, including its intellectual property.
$75 million funded at closing on September 4, 2026; up to $325 million more available subject to milestones
Loans bear interest at the greater of 3.00% or one-month SOFR plus 6.15%, and mature September 4, 2031
Obligations secured on a first-priority basis by substantially all assets, including intellectual property
Covenants require at least $50 million of liquidity in controlled accounts until FDA approves the lonvo-z BLA
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Intellia Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →